Find a Physician

findphysician

From a family practitioner to the most sophisticated neurologists, JFK Medical Center's staff includes some of the most highly respected physicians in the northeast. For a referral to a JFK physician, click here.

JFKTV

video pregnancy

Congratulations to JFK Family Medicine Center: Center for Pregnancy for being selected as a 2015 Community Leader of Distinction!

Print

Clinical Trials

Developing the Future of Medicine

At JFK Medical Center, the following clinical trials have IRB approval for enrollment. JFK Medical Center is an Affiliate of the Rutgers Cancer Institute of New Jersey. As an Affiliate, access to other clinical trials is available.

Updated 5/14/2018 

JFK MEDICAL CENTER CLINICAL TRIALS

Brain

Diffusion 100-206 – Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

BMS CA209-498 – A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT Glioblastoma

BMS CA209-548 - A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in 68 Newly Diagnosed Adult Subjects with MGMT – Methylated Glioblastoma

Tg 511-15-01 - A Phase 2/3 Randomized Open Label Study of Toca 511, a Retroviral Replicating Vector, Combined with Toca FC versus Standard 511-15-01 of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Vigilant - Vigilant ObservatIon of GlIadeL WAfer ImplaNT (VIGILANT) Registry: A Multicenter, Observational Registry to Collect Information on the Safety and Effectiveness of Gliadel® Wafer (Carmustine Implant) Used in Usual Medical Practice

RCCA TRIALS

DLBCL

InCB 50465-202 - A phase 2 multicenter international open label safety and efficacy study of INCB 050465 in subjects with relapsed or refractory diffused large B cell lymphoma

Follicular/Marginal Zone/or Mantle Cell Lymphoma

Celgene CC-5013-NHL-008 - Magnify - A phase 3 B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide single agent maintenance vs rituxamab maintenance in subjects with relapsed/refractory follicular, marginal zone or mangle cell lymphoma

INCB 50465-203 - A phase 2 multicenter open label study of INCB050465, a P13K inhibitor in relapsed or refractory follicular lymphoma

INCB 50465-204 - Phase 2 open label 2 cohort study of INCB 050465 a P13K inhibitor in subjects with relapsed or refractory marginal zone lymphoma with or without prior exposure to a BTK inhibitor

INCB 50465-205 - A phase 2 open label 2 cohort multicenter study of INCB 50465 a P14k inhibitor in relapsed or refractory mantle cell lymphoma previously treated with or without a BTK inhibitor

Acerta ACE-LY-003 – Phase 1b/2 open label study of alcalabrutinib alone or in combination with rituxan in subjects with indolent b-cell NHL

Metastatic Disease

Horizon BCBS - Observational GPS study for patient with patients who have Horizon BCBS insurance and metastatic disease

Multiple Myeloma

Millenium C16021 - A phase 3 randomized, placebo-controlled double blind study of oral ixazomib maintenance therapy after initial therapy in patients with newly diagnosed multiple myeloma not treated with stem cell transplant

Ovarian Cancer

Astrazenca light D018161003 - Non randomized open label phase 2 study to access oliparib tablets as a treatment for subjects with different HRD tumor status and with platinum sensitive, relapsed, high grade or high grade endometriod ovarian, fallopian tube of primary periotoneal cancer that have received at least 1 prior line of chemo

Pancreatic

CanStem111P - Phase 3 open label randomized, study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemzar (arm 1) vs nab-paclitaxel with gemzar (arm 2) in metastatic disease

Multiple Myeloma

Millenium C16021 - A phase 3 randomized, placebo-controlled double blind study of oral ixazomib maintenance therapy after initial therapy in patients with newly diagnosed multiple myeloma not treated with stem cell transplant

If you have any questions regarding any of the clinical trials, please call: Elizabeth Murray, Clinical Research Coordinator (732) 321-7000, ext. 61689 or email ElizabethM.Murray@hackensackmeridian.org.